FilingsTodayDaewoong Pharma
At a glance
Daewoong Pharma filed 56 disclosures in the last 12 months, including 7 insider, 4 earnings, 2 contract and 1 5% holder. The most recent key filing was on Aug 21.
Revenue for 2025 was ₩1.57T, up 10.4% on 2024. Operating margin was 12.5% against 10.4% a year earlier. Debt was 108% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩826B and operating profit of ₩90.3B.
The 2025 annual report lists 1,794 employees with an average tenure of 6.8 years and average pay of ₩77.2M, #437 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩302M each on average. It paid ₩600 per common share in cash dividends, against ₩600 a year earlier (+0%). (주)대웅 and related parties held 61.34% at year end.
From the 2025 annual report
Staff: 1,794 (1,136 men, 658 women), of whom 52 on fixed-term contracts. Total pay for the year: ₩139B. Directors and auditors: 6, paid ₩1.8B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩600 | ₩600 | ₩600 |
| Payout ratio | 3.5% | 27.9% | 5.7% |
| Yield (as filed) | 0.30% | 0.50% | 0.50% |
| Total cash dividends | ₩6.9B | ₩6.9B | ₩6.9B |
Largest shareholder
(주)대웅 holds 52.29%; with 7 related parties the group holds 61.34% of common shares at year end (from 61.46% at the start of the year).
Individuals paid ₩500M or more
| 이창재 대표이사 | ₩801M |
| 박성수 대표이사 | ₩588M |
Auditor: 한영회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.